UPDATE: AbbVie (ABBV) Guides Q3 EPS Below Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to UPDATE: AbbVie (ABBV) Guides Q3 EPS Below Views

AbbVie (ABBV) Tops Q2 EPS by 2c

July 24, 2015 7:53 AM EDT

AbbVie (NYSE: ABBV) reported Q2 EPS of $1.08, $0.02 better than the analyst estimate of $1.06. Revenue for the quarter came in at $5.48 billion versus the consensus estimate of $5.62 billion.

Key Events from the Second Quarter

On May 26, AbbVie successfully completed the acquisition of Pharmacyclics, accelerating AbbVie's clinical and commercial presence in oncology. The acquisition aligns strategically to AbbVie's business model, strengthening the company's already robust oncology pipeline and further diversifying AbbVie's revenue base.AbbVie announced that the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option specifically... More